Y-mAbs is a clinical-stage biopharmaceutical company focused on immunotherapies for cancer, with lead antibody programs targeting GD2 and B7-H3. Its pipeline includes two lead compounds, burtomab and naxitamab, and platform technologies to create humanized, affinity-matured bispecific antibodies. The company is collaborating on a novel human protein tag that dimerizes T-cell engaging bispecifics to improve tumor binding, extend serum half-life, and increase T-cell–mediated tumor cell killing. Y-mAbs aims to drive multiple product candidates in select solid tumors to FDA approval and to reduce long-term toxicities compared with existing chemotherapies. The company plans to advance its next wave of candidate medicines into clinical trials and to build commercial organization and sales and marketing capabilities as programs near approval.

Total raised

$30M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2017